Liraglutide vs. Sulphonylurea with Metformin During Ramadan: Efficacy and Safety in Type 2 Diabetes Explored

Managing Type 2 Diabetes Mellitus (T2DM) during Ramadan presents unique challenges, as fasting can significantly alter glycemic control, increasing risks of hypoglycemia and hyperglycemia. Current standard-of-care often involves sulphonylureas (SUs), which stimulate insulin secretion but carry a notable risk of hypoglycemia, especially during prolonged fasting. GLP-1 receptor agonists like liraglutide offer a different mechanism, enhancing glucose-dependent insulin secretion and suppressing glucagon, with a lower inherent risk of hypoglycemia compared to SUs. There's a critical need for comparative data on these agents, particularly in combination with metformin, to guide safer and more effective treatment strategies for T2DM patients observing Ramadan.

This trial, conducted across Africa and Asia, aimed to compare the efficacy and safety of liraglutide versus a sulphonylurea (SU), both administered in combination with metformin, in subjects with Type 2 Diabetes during the fasting month of Ramadan. The study design is described as a randomized, open-labeled, parallel-group trial, comparing these two treatment regimens. Specific details regarding patient numbers (n), exact doses of liraglutide or the specific sulphonylurea, administration routes, frequency, duration, or primary endpoints were not provided in the abstract. The study's objective was to assess the comparative performance of these combination therapies under real-world fasting conditions.

The provided abstract outlines the aim of the trial, which is to investigate the efficacy and safety of liraglutide versus sulphonylurea, both in combination with metformin, during Ramadan in subjects with Type 2 Diabetes. However, specific results, statistical data, or quantitative findings from the trial were not included in the abstract. Therefore, no conclusions regarding the comparative efficacy, safety profiles, or specific outcomes of liraglutide versus sulphonylurea in this context can be reported at this time. The abstract focuses solely on the study's objective and geographical scope, without detailing any observed changes in HbA1c, glucose levels, hypoglycemic events, or other relevant clinical markers.